The Studies Of Utilizing Technology Development Of Astringent Persimmon (Diospyros Kaki Thunberg) In Korea

A Persimmon is one of fruits with a long history in Korea. Persimmons are classified a sweet persimmon and astringent persimmon. From old times, the stalk of astringent persimmon has been called Kaki Calyx and used in traditional Korean medicine (TKM) [1]. The materials collected Gogongsi from Sancheong, Danseongsi from Sancheong, and Bansi from Miryang with different kinds of cultivar. The samples were provided from Forest Environment Research Institute in Gyeongsangnamdo, Korea. These materials were separated from astringent persimmon to its stalks and peels. The separated samples were identified microorganisms, analyzed tannic acids, checked toxicity, and tested their anti-inflammatory properties. As a result, tannic acids were included in all of samples and the persimmons. Bansi from Miryang had high percentage of the content compared with other samples. 70% EtOH extractions from each sample in MTT test has been safe in toxicity levels. Three samples among the samples have an effective of inhibiting inflammatory. This study would provide useful information about microbial identification, tannic acid content, and safety to contribute chances for increasing the income of farmers through utilizing technology development of astringent persimmon. To future study, we will be required to extend any other area and species. We have planned to identify microbiology, analyze tannic acid content depending on sampling times and various symptoms and test of NO inhibition.

Acknowledgements: This work was supported by The Study of Utilizing Technology Development of Astringent Persimmon (G15050), Construction of the infrastructure for traditional Korean medicine clinical trials and establishment of the evidence for efficacy and safety of herbal medicine (K15121), Establishment of Molecular Authentication System and Development of Seedling Proliferation Techniques for the Production of Authentic Herbal Medicines (K15421), the Korea Institute of Oriental Medicine (KIOM) to the Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea.

Reference: [1] The Korean Pharmacopoeia 10th edition. The KFDA Notification No. 2012 – 129. 2012. Dec 27th. Korea Food & Drug Administration.